A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1361 | Th1051 | Human Serum Albumin | MKWVTFISLLFLFSSAYSRG Full view | 609 | Ia | Hematological/Metabolic/genetic | Albuminar | CSL Behring | Sterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. | Albumin (Human) 25%, Albuminar-25 (albumin human) , is to be administered by the Intravenous route. | Serum substitutes | N.A. |
1362 | Th1051 | Human Serum Albumin | MKWVTFISLLFLFSSAYSRG Full view | 609 | Ia | Hematological/Metabolic/genetic | Albutein | GRIFOLS | Sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). | Albutein 20% is to be administered by the Intravenous route. | Serum substitutes | N.A. |
1365 | Th1053 | Serum albumin iodonated | MKWVTFISLLFLFSSAYSRG Full view | 600 | IV | Hematological Disorders | Megatope | IsoTex Diagnostics | Colorless to very pale yellow solutions | Injection for Intravenous administration | Diagnostic Agents | Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
1366 | Th1053 | Serum albumin iodonated | MKWVTFISLLFLFSSAYSRG Full view | 600 | IV | Hematological Disorders | Jeanotope | IsoTex Diagnostics | Sterile, nonpyrogenic, aqueos solution | Intravenous infusion | Diagnostic Agents | Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
1367 | Th1053 | Serum albumin iodonated | MKWVTFISLLFLFSSAYSRG Full view | 600 | IV | Hematological Disorders | Volumex | IsoTex Diagnostics | Colorless to very pale yellow. | Intravenous infusion | Diagnostic Agents | Apolipoprotein E,Serum amyloid A-1 protein,Protein AMBP |
1381 | Th1059 | Hyaluronidase | MWTGLGPAVTLALVLVVAWA Full view | 476 | Ic | Adjunct Therapy | HYLENEX | Baxter Healthcare Corporation | Sterile, clear, colorless, nonpreserved, ready for use solution. | Human Injection Subcutaneous use | Adjuvants, Anesthesia and Permeabilizing Agents | N.A. |
1389 | Th1062 | Rituximab | Heavy Chain: QVQLQQP Full view | 664 | IIa | Cancer/Immunological | Rituxan | Biogen Idec Inc., and Genentech USA, Inc | Sterile, clear, colorless, preservative-free liquid concentrate |  Intravenous administration | Antineoplastic Agents, Immunologic Factors and Antirheumatic Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
1398 | Th1063 | Basiliximab | Heavy Chain: QLQQSGT Full view | 657 | IIa | Immunological | Simulect | Novartis | Sterile lyophilisate which is available in 6 mL colorless glass vials and is available in 10 mg and 20 mg strength | intravenous infusion mainly or bolus (if no allergic reactions occurs) | Immunosuppressive Agents | N.A. |
1400 | Th1064 | Muromonab | Heavy Chain: QVQLQQS Full view | 664 | IIa | Immunological | ORTHOCLONE OKT3 STERILE SOLUTION | Centocor Ortho Biotech, L.P. | Sterile Solution is a murine monoclonal antibody to the CD3 antigen of human T cells which functions as an immunosuppressant. | For Intravenous Use Only | Immunologic Factors and Immunosuppressive Agents | N.A. |
1403 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DIGIBIND | Galaxo Smith Kline | Sterile lyophilized powder of antigen binding fragments (Fab) derived from specific antidigoxin antibodies raised in sheep. | Intravenous infusion after reconstitution with Sterile Water for Injection | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1404 | Th1065 | Digoxin Immune Fab (Ovine) | Heavy Chain: EVQLQQS Full view | 438 | IIa | Cardiac | DigiFab |  Protherics Inc | Sterile, purified, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments. | Intravenous administration | Antidotes | T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, T-cell surface glycoprotein CD3 gamma chain, T-cell surface glycoprotein CD3 zeta chain, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1406 | Th1066 | Ibritumomab | Heavy Chain: QAYLQQS Full view | 652 | IIb | Cancer | Zevalin | Spectrum Pharmaceuticals | Clear, colorless, sterile, pyrogen-free, preservative-free solution that may contain translucent particles. | Intravenous infusion | N.A. | Digoxin |
1428 | Th1072 | Streptokinase | MKNYLSFGMFALLFALTFGT Full view | 440 | Ic | Metabolic/Haemetological | Streptase | CSL Behring | Sterile, purified preparation formulated as lypholized powder | Intravenous and intracoronary administration. | Fibrinolytic Agents and Thrombolytic Agents | N.A. |
1434 | Th1074 | Alglucerase | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Metabolic | Ceredase | Genzyme Corporation | Clear sterile non-pyrogenic solution of alglucerase in a citrate buffered solution | Intravenous injection | Enzyme Replacement Agents | Plasminogen,Proteinase-activated receptor 1 |
1437 | Th1076 | Laronidase | APHLVQVDAARALWPLRRFW Full view | 626 | Ia | Metabolic | ALDURAZYME | Genzyme Corporation | Sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection | Intravenous infusion | Enzyme Replacement Agents | N.A. |
1445 | Th1079 | Serum Albumin | DAHKSEVAHRFKDLGEENFK Full view | 585 | IV | Metabolic/genetic | Albunex | Mallinckrodt; Tyco Healthcare | N.A. | Intravenous infusion | Serum substitutes | N.A. |
1446 | Th1079 | Serum Albumin | DAHKSEVAHRFKDLGEENFK Full view | 585 | IV | Metabolic/genetic | Optison | GE Healthcare | N.A. | Intravenous infusion | Serum substitutes | N.A. |
1453 | Th1083 | Coagulation Factor Ix | YNSGKLEEFVQGNLERECME Full view | 415 | Ia | Hematological/Metabolic/genetic | Alprolix | Biogen Idec Inc., and Genentech USA, Inc | Sterile, non-pyrogenic, preservative-free, white to off-white, lyophilized powder to cake for reconstitution with the provided diluent | Intravenous infusion | Coagulants and Thrombotic Agents | N.A. |
1466 | Th1090 | Daclizumab | QVQLVQSGAEVKKPGSSVKV Full view | 674 | IIa | Immunologicals | Zenapax | Roche | Clear, sterile, colorless concentrate for further dilution and intravenous administration | Intravenous injection | Immunosuppressive Agents | Fusion glycoprotein F0,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
1475 | Th1095 | Ranibizumab | Light Chain SASQDISN Full view | 447 | IIa | Hematological/Eye Disorder | Lucentis | Genentech | Sterile, colorless to pale yellow solution | Intravitreal injection | Ophthalmics | Vascular endothelial growth factor A |
1476 | Th1096 | Idursulfase | SETQANSTTDALNVLLIIVD Full view | 525 | Ia | Metabolic | Elaprase | SHIRE | Sterile, nonpyrogenic clear to slightly opalescent, colorless solution that must be diluted prior to administration in 0.9% Sodium Chloride Injection, USP | Intravenous infusion | Enzyme Replacement Agents | Dermatan sulfate,Heparan sulfate,Perilipin-3 |
1494 | Th1101 | Galsulfase | SGAGASRPPHLVFLLADDLG Full view | 497 | Ia | Metabolic | Naglazyme | BioMarin | Sterile, nonpyrogenic, colorless to pale yellow, clear to slightly opalescent solution that must be diluted with 0.9% Sodium Chloride Injection, USP, prior to administration | Intravenous infusion | Enzyme Replacement Agents | Dermatan sulfate,Perilipin-3 |
1548 | Th1117 | Ipilimumab | Heavy chain: QVQLVES Full view | 663 | IIIc | Cancer | YERVOY | Bristol-Myers Squibb | Sterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solution | N.A. | Antineoplastic Agents and Monoclonal antibodies | Cytotoxic T-lymphocyte protein 4 |
1560 | Th1121 | Pertuzumab | light chain DIQMTQSP Full view | 664 | IIIc | Cancer | Perjeta | Genentech | Sterile, clear to slightly opalescent, colorless to pale brown liquid | Intravenous infusion | Monoclonal antibodies | Receptor tyrosine-protein kinase erbB-2 |
1570 | Th1123 | Denosumab | Heavy chain EVQLLESG Full view | 664 | IIIc | Osteological | Xgeva | Amgen. | Sterile, preservative-free, clear, colorless to pale yellow solution | N.A. | Bone Density Conservation Agents and Monoclonal antibodies | Tumor necrosis factor ligand superfamily member 11 |
1571 | Th1123 | Denosumab | Heavy chain EVQLLESG Full view | 664 | IIIc | Osteological | Prolia | Amgen. | Sterile, preservative-free, clear, colorless to pale yellow solution | N.A. | Bone Density Conservation Agents and Monoclonal antibodies | Tumor necrosis factor ligand superfamily member 11 |
1602 | Th1128 | Velaglucerase Alfa | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Hormonal | VPRIV | Shire | Sterile, preservative free, lyophilized powder | Intravenous infusion | Enzymes | Glucosylceramidase |
1604 | Th1130 | Brentuximab Vedotin | Heavy chain:QIQLQQSG Full view | 664 | IIb | Cancer | Adcetris | Seattle Genetics | Sterile, white to off-white, preservative-free lyophilized cake or powder in single-use vials. | Intravenous infusion | N.A. | Tumor necrosis factor receptor superfamily member 8 |
1608 | Th1131 | Taliglucerase Alfa | EFARPCIPKSFGYSSVVCVC Full view | 504 | Ia | Hormonal | Elelyso | Pfizer | Sterile, non-pyrogenic, lyophilized product. | Intravenous infusion | Enzymes | Glucocerebroside |
1615 | Th1133 | Aflibercept | SDTGRPFVEMYSEIPEIIHM Full view | 431 | Ib | Cancer | Eylea | Regeneron Pharmaceuticals | Sterile, clear, and colorless to pale yellow solution. | Intravitreal injection | Antineoplastic Agents and Ophthalmics | Vascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
1616 | Th1133 | Aflibercept | SDTGRPFVEMYSEIPEIIHM Full view | 431 | Ib | Cancer | Zaltrap | Sanofi and Regeneron Pharmaceuticals, Inc. | Sterile, clear, colorless to pale yellow, non-pyrogenic, preservative-free, solution. | Intravenous infusion | Antineoplastic Agents and Ophthalmics | Vascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
1628 | Th1139 | Certolizumab Pegol | Light chain: DIQMTQS Full view | 443 | IIb | Immunologcal | Cimzia | UCB | Sterile, white, lyophilized powder for solution or as a sterile, solution in a single-use prefilled 1 mL glass syringe | Subcutaneous injection | TNF inhibitor | Tumor necrosis factor |
1637 | Th1143 | Fibrinolysin Aka Plasmin | Fibrinolysin heavy c Full view | 786 | Ic | Hematological | Elase | N.A. | N.A. | N.A. | N.A. | N.A. |
1654 | Th1150 | Secukinumab | Secukinumab Heavy Ch Full view | 672 | IIa | Immunological | Cosentyx | Novartis Pharmaceuticals Corporation | Sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. | Subcutaneous injection | Inhibitor | IL-17A cytokine |
1659 | Th1152 | Drotrecogin alfa | Heavy Chain: LIDGKMT Full view | 402 | Ib | Infectious | Xigris | Eli Lilly and Company | Sterile, lyophilized, white to off-white powder | Intravenous Infusion | Antisepsis | Coagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
1661 | Th1153 | Alefacept | Heavy Chain: CFSQQIY Full view | 705 | IIa | Immunological | Amevive | Astellas Pharma Inc. | Sterile, white-to-off-white, preservative-free, lyophilized powder | Intramuscular Injection | Dermatologic and Immunosupressive agents | T-cell surface antigen CD2, Complement C1r subcomponent, Complement C1q subcomponent subunit A, B, C, Low affinity immunoglobulin gamma Fc region receptor III-A,III-B, II-a, II-b, II-c |
1671 | Th1159 | Gemtuzumab ozogamicin | Light Chain 1: QIVLT Full view | 459 | IIb | Cancer | Mylotarg | Wyeth pharmaceuticals inc | Sterile, white, preservative-free lyophilized powder | Intravenous infusion | Antineoplastic agents and Immunotoxins | Myeloid cell surface antigen CD33, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1674 | Th1161 | Albiglutide | HGEGTFTSDVSSYLEGQAAK Full view | 645 | Ib | Hormonal disorders | Eperzan | Glaxosmithkline Inc | Powder for Solution | Subcutaneous | Drugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. | Glucagon-like peptide 1 receptor |
1676 | Th1161 | Albiglutide | HGEGTFTSDVSSYLEGQAAK Full view | 645 | Ib | Hormonal disorders | Tanzeum | Glaxo Smith Kline Llc | Injection, Powder, Lyophilized, for Solution | Subcutaneous | Drugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. | Glucagon-like peptide 1 receptor |
1694 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharma Ghbh | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
1695 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharmaceuticals Inc. | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
1708 | Th1170 | Blinatumomab | DIQLTQSPASLAVSLGQRAT Full view | 504 | IIIc | Cancer/Genetic | Blincyto | AMGEN | Lyophilized Powder for intravenous administration | Intravenous | Antineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents | B-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain |
1736 | Th1177 | Elosulfase alfa | APQPPNILLLLMDDMGWGDL Full view | 496 | Ia | Metabolic Disorders | Vimizim | Biomarin International Limited | Solution | Intravenous | Enzymes; Alimentary Tract and Metabolism | N-acetylgalactosamine-6-sulfatase |
1738 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | NA | NA | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | SLAM family member 7 |
1739 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 8 |
1740 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 9 |
1797 | Th1191 | Vedolizumab | Heavy Chain Sequence Full view | 716 | IIa | Immunological Disorders | Entyvio | Takeda Pharmaceuticals America, Inc. | Injection, Powder, Lyophilized, for Solution | Intravenous | Immunosupressive agent, Antineoplastic agent | Integrin alpha-4, Integrin beta-7 |
1802 | Th1196 | Siltuximab | Heavy Chain Sequence Full view | 708 | IIa | Immunological Disorders | Sylvant | Janssen Inc | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents, Immunosuppressive Agents | Interleukin-6 |
1811 | Th1202 | Pembrolizumab | Heavy Chain Sequence Full view | 711 | IIIc | Cancer | Keytruda | Merck Sharp & Dohme Corp. | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
1813 | Th1204 | Ofatumumab | Ofatumumab Heavy Cha Full view | 483 | IIIc | Cancer | Arzerra | Glaxo Smith Kline Llc | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents |